{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:06:30Z","timestamp":1783926390183,"version":"3.55.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.119055","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:48:25Z","timestamp":1781308105000},"page":"119055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery and evaluation of a 4-(benzothiazol-2-yl)-N-substituted aniline scaffold as MERS-CoV inhibitors"],"prefix":"10.1016","volume":"316","author":[{"given":"Kaili","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minqi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0411-7391","authenticated-orcid":false,"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119055_bib1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: recent insights into emerging coronaviruses","volume":"14","author":"de Wit","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119055_bib2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejmech.2026.119055_bib3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119055_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106192","article-title":"In-line treatments and clinical initiatives to fight against COVID-19 outbreak","volume":"191","author":"Agrawal","year":"2022","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejmech.2026.119055_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119055_bib10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119055_bib11","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1126\/science.1116480","article-title":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor","volume":"309","author":"Li","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119055_bib12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119055_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature12328","article-title":"Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26","volume":"500","author":"Lu","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119055_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119055_bib15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/v17070989","article-title":"Entry inhibitors of SARS-CoV-2 targeting the transmembrane domain of the spike protein","volume":"17","author":"Lyles","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.119055_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14728222.2017.1271415","article-title":"MERS-CoV spike protein: a key target for antivirals","volume":"21","author":"Du","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2026.119055_bib17","article-title":"1,2,3,4,6-Pentagalloyl glucose, a RBD-ACE2 binding inhibitor to prevent SARS-CoV-2 infection","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119055_bib18","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3390\/v16091433","article-title":"MoMo30 binds to SARS-CoV-2 spike variants and blocks infection by SARS-CoV-2 pseudovirus","volume":"16","author":"DeBarros","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.119055_bib19","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2413465122","article-title":"Structure-guided engineering of a mutation-tolerant inhibitor peptide against variable SARS-CoV-2 spikes","volume":"122","author":"Nakamura","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.119055_bib20","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119055_bib21","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119055_bib22","doi-asserted-by":"crossref","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119055_bib23","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119055_bib24","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1021\/acs.jmedchem.0c01140","article-title":"Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities","volume":"65","author":"Cannalire","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119055_bib25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2026.119055_bib26","doi-asserted-by":"crossref","first-page":"eaav4580","DOI":"10.1126\/sciadv.aav4580","article-title":"A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike","volume":"5","author":"Xia","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2026.119055_bib27","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/ncomms4067","article-title":"Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor","volume":"5","author":"Lu","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119055_bib28","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/infdis\/jiv325","article-title":"Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection","volume":"212","author":"Channappanavar","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119055_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/v14030597","article-title":"A five-helix-based SARS-CoV-2 fusion inhibitor targeting heptad repeat 2 domain against SARS-CoV-2 and its variants of concern","volume":"14","author":"Xing","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.119055_bib30","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119055_bib31","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab\u2013Cilgavimab) for prevention of Covid-19","volume":"386","author":"Levin Myron","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119055_bib32","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/s41467-023-37290-6","article-title":"Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive omicron subvariants","volume":"14","author":"Maekelae","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119055_bib33","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1128\/JVI.00912-14","article-title":"Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies","volume":"88","author":"Ying","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119055_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110812","article-title":"LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants","volume":"39","author":"Westendorf","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119055_bib35","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A5368","article-title":"CeSPIACE, a novel peptide SARS-CoV-2 spike inhibitor, prevents and treats COVID-ARDS: findings from a mouse ARDS model","volume":"211","author":"Osawa","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2026.119055_bib36","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.abd9909","article-title":"De novo design of picomolar SARS-CoV-2 miniprotein inhibitors","volume":"370","author":"Cao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119055_bib37","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.chom.2021.06.008","article-title":"Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease","volume":"29","author":"Case","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ejmech.2026.119055_bib38","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/s41589-022-01060-0","article-title":"A dimeric proteomimetic prevents SARS-CoV-2 infection by dimerizing the spike protein","volume":"18","author":"Khatri","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119055_bib39","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3349\/ymj.2021.62.11.961","article-title":"SARS-CoV-2 variants of concern","volume":"62","author":"Choi","year":"2021","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.ejmech.2026.119055_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-031-28012-2_1","article-title":"The COVID-19 pandemic: SARS-CoV-2 structure, infection, transmission, symptomology, and variants of concern","volume":"1412","author":"Guest","year":"2023","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2026.119055_bib41","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119055_bib42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nri2747","article-title":"Strategies and challenges for the next generation of therapeutic antibodies","volume":"10","author":"Beck","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2026.119055_bib43","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ijantimicag.2018.05.003","article-title":"Safe, high-throughput screening of natural compounds of MERS-CoV entry inhibitors using a pseudovirus expressing MERS-CoV spike protein","volume":"52","author":"Kim","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2026.119055_bib44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/13102818.2022.2158133","article-title":"Antiviral activity of Humulus lupulus (HOP) aqueous extract against MERS-CoV and SARS-CoV-2: in-vitro and in-silico study","volume":"37","author":"Bouback","year":"2023","journal-title":"Biotechnol. Biotec. Eq."},{"key":"10.1016\/j.ejmech.2026.119055_bib45","doi-asserted-by":"crossref","first-page":"43299","DOI":"10.1039\/D0RA08442E","article-title":"1-Phenyl-N-(benzothiazol-2-yl)methanimine derivatives as Middle East respiratory syndrome coronavirus inhibitors","volume":"10","author":"Hu","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.119055_bib46","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1021\/jm9600959","article-title":"Antitumor benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo","volume":"39","author":"Shi","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119055_bib47","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119055_bib48","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01218-20","article-title":"Broad anti-coronavirus activity of food and drug Administration-approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo","volume":"94","author":"Weston","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119055_bib49","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/infdis\/jiw080","article-title":"Prophylaxis with a Middle East respiratory syndrome coronavirus (MERS-CoV)-specific human monoclonal antibody protects rabbits from MERS-CoV infection","volume":"213","author":"Houser","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119055_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/srep31629","article-title":"Passive transfer of a germline-like neutralizing human monoclonal antibody protects transgenic mice against lethal Middle East respiratory syndrome coronavirus infection","volume":"6","author":"Agrawal","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119055_bib51","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119055_bib52","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.addr.2007.05.010","article-title":"Salt formation to improve drug solubility","volume":"59","author":"Serajuddin","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2026.119055_bib53","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41422-021-00570-1","article-title":"Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2","volume":"31","author":"Xie","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2026.119055_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115760","article-title":"Designed miniproteins potently inhibit and protect against MERS-CoV","volume":"44","author":"Ragotte","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119055_bib55","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41421-025-00827-8","article-title":"Dual-targeting strategy enables extremely potent and broad inhibition of emerging MERS-related coronaviruses","volume":"11","author":"Jiao","year":"2025","journal-title":"Cell Discov."},{"key":"10.1016\/j.ejmech.2026.119055_bib56","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.cell.2025.01.012","article-title":"Early fusion intermediate of ACE2-using coronavirus spike acting as an antiviral target","volume":"188","author":"Xing","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119055_bib57","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.3390\/ijms26125729","article-title":"A dual-targeting peptide inhibitor simultaneously blocking viral attachment and membrane fusion for broad-spectrum inhibition of SARS-CoV-2","volume":"26","author":"Bi","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119055_bib58","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/jps.20792","article-title":"Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications","volume":"96","author":"Kaufmann","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2026.119055_bib59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000315101","article-title":"Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications","volume":"26","author":"Kornhuber","year":"2010","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejmech.2026.119055_bib60","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1126\/science.abi4708","article-title":"Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2","volume":"373","author":"Tummino","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119055_bib61","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41419-020-02842-x","article-title":"On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2","volume":"11","author":"Sauvat","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2026.119055_bib62","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1128\/JVI.01429-16","article-title":"Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion","volume":"90","author":"Coleman","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119055_bib63","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1038\/s41598-022-09664-1","article-title":"Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism","volume":"12","author":"Strobelt","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119055_bib64","article-title":"Lysosomal adaptation: how cells respond to lysosomotropic compounds","volume":"12","author":"Lu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119055_bib65","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/s41401-020-00556-6","article-title":"Identification of SARS-CoV-2 entry inhibitors among already approved drugs","volume":"42","author":"Yang","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2026.119055_bib66","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.celrep.2018.06.041","article-title":"Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV spike glycoprotein","volume":"24","author":"Zhang","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119055_bib67","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1126\/scitranslmed.3008140","article-title":"Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein","volume":"6","author":"Jiang","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119055_bib68","article-title":"Cryoelectron microscopy structures of a human neutralizing antibody bound to MERS-CoV spike glycoprotein","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119055_bib69","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1038\/s41467-019-10897-4","article-title":"Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119055_bib70","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.3390\/ijms26104772","article-title":"Application of lipophilic prodrug charge masking strategy to obtain novel, potential oxytocin prodrugs","volume":"26","author":"Gitlin-Domagalska","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119055_bib71","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","article-title":"Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment","volume":"182","author":"Sun","year":"2020","journal-title":"Cell"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:20:12Z","timestamp":1783923612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426005003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":67,"alternative-id":["S0223523426005003"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119055","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and evaluation of a 4-(benzothiazol-2-yl)-N-substituted aniline scaffold as MERS-CoV inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119055"}}